22 August @ 7:30 pm – 8:30 pm AEST
Click here to register.
The therapeutic landscape for PsA continues to expand. Patients and prescribers now have a wide range of options for disease management. Traditional DMARDs, biologics, and targeted synthetic DMARDs have revolutionised the treatment of PsA, providing improved patient outcomes and quality of life.
As research and development in this field continue to progress, the future holds promise for even more innovative therapeutic agents and tailored treatment strategies to manage PsA. Please join Caravaggio aficionado, Prof Peter Nash (a rockstar in the world of rheumatology) and A/Prof Peter Foley as we discuss some of these exciting new options.
Click here to register.
